Medication in Parkinson's: Research papers
- Apomorphine injections: Predictors of initial common adverse events and long term tolerability
Conclusion: A previous history of nausea and hypotension, and older age should not dissuade a trial of apomorphine if clinically justified. A three day pre-treatment dose of trimethobenzamide, as recommended in the United States, does not reduce nausea.
26 January 2012
- Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert
Vitamin B12 supplementation may need to be considered in PD patients on duodenal levodopa infusion therapy. Vitamin B12 deficiency in patients on duodenal levodopa infusion therapy may be more frequent than the published data suggest. We must be alert.
24 January 2012
- Paradoxical worsening of gait with levodopa in Parkinson disease
While there are many "nondopaminergic" features of PD that do not improve with levodopa, PD motor symptoms generally improve with dopaminergic medications. However, not all the motor manifestations of PD are improved to the same extent and some may not respond at all to levodopa. Tremor is often less responsive to levodopa than bradykinesia.
18 January 2012
- A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
Exploratory analysis of the primary endpoint for 100 mg/day demonstrated that the addition of safinamide to a stable dose of DA improves motor symptoms in early PD and warrants further investigation.
15 January 2012
- The Q10 questionnaire for detection of wearing-off phenomena in Parkinson's disease
Q10 items were selected from the QUICK validation study data set through statistical analysis and it was then tested on a sample of 162 PD patients, 64.8% with wearing-off. Sensitivity, specificity, and accuracy were 96%, 63%, and 85% respectively with one positive response and 90%, 70%, and 83% respectively with two positive responses.
12 January 2012
- ''On'' state freezing of gait in Parkinson disease: A paradoxical levodopa-induced complication
Conclusions: True on FOG exists as a rare phenotype in PD, unassociated with cognitive impairment or a predating off FOG. Distinguishing the different FOG subtypes requires a comprehensive motor assessment in at least 3 medication states.
12 January 2012
